ATE209680T1 - Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen - Google Patents

Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen

Info

Publication number
ATE209680T1
ATE209680T1 AT96913954T AT96913954T ATE209680T1 AT E209680 T1 ATE209680 T1 AT E209680T1 AT 96913954 T AT96913954 T AT 96913954T AT 96913954 T AT96913954 T AT 96913954T AT E209680 T1 ATE209680 T1 AT E209680T1
Authority
AT
Austria
Prior art keywords
molecules
nucleic acid
acid molecules
hla
mhc
Prior art date
Application number
AT96913954T
Other languages
English (en)
Inventor
Yannick Guilloux
Francine Jotereau
Thierry Boon-Falleur
Sophie Lucas
Vincent Brichard
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE209680T1 publication Critical patent/ATE209680T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
AT96913954T 1995-06-07 1996-05-07 Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen ATE209680T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/487,135 US5821122A (en) 1995-06-07 1995-06-07 Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
PCT/US1996/006409 WO1996040039A2 (en) 1995-06-07 1996-05-07 Isolated nucleic acid molecules, peptides which form complexes with mhc molecule hla-a2 and uses thereof

Publications (1)

Publication Number Publication Date
ATE209680T1 true ATE209680T1 (de) 2001-12-15

Family

ID=23934549

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96913954T ATE209680T1 (de) 1995-06-07 1996-05-07 Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen

Country Status (12)

Country Link
US (3) US5821122A (de)
EP (1) EP0845032B1 (de)
JP (1) JP3849102B2 (de)
AT (1) ATE209680T1 (de)
AU (1) AU704934B2 (de)
CA (1) CA2223694C (de)
DE (1) DE69617440T2 (de)
DK (1) DK0845032T3 (de)
ES (1) ES2167561T3 (de)
PT (1) PT845032E (de)
WO (1) WO1996040039A2 (de)
ZA (1) ZA963907B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839765D1 (de) 1997-01-27 2008-09-04 Ludwig Inst Cancer Res Lage-1 tumor-assozierte nukleinsäuren
US6680191B1 (en) 1997-04-25 2004-01-20 Ludwig Institute For Cancer Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
AU2001229681A1 (en) * 2000-01-20 2001-07-31 Ludwig Institute For Cancer Research Mage antigenic peptides which bind hla-b35 and hla-b44
ATE438409T1 (de) 2000-09-15 2009-08-15 Pasteur Institut Proteinhaltigen vektoren zur einführung von moleküle in cd11b exprimirende zellen
CA2433877C (en) 2001-01-17 2014-11-18 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6607151B2 (en) * 2001-08-16 2003-08-19 Morris Samelson Ultra fine dead sea mineral compound and method of manufacture
EP3020413A1 (de) 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Zusammensetzungen und Verfahren im Zusammenhang mit TIM-3, A TH1-spezifischem Zelloberflächenmolekül
US20070026022A1 (en) * 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
CA2546452C (en) * 2003-11-21 2015-01-20 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
EP2332971B1 (de) * 2004-06-17 2016-02-17 MannKind Corporation Epitop-Analoga
CN101057145B (zh) 2004-06-23 2014-10-22 得克萨斯系统大学评议会 使用双粒子复合体检测生物分子的方法和组合物
US8481297B2 (en) 2009-01-08 2013-07-09 Yale University Compositions and methods of use of an oncolytic vesicular stomatitis virus
WO2011032003A1 (en) 2009-09-10 2011-03-17 Yale University Immunization to reduce neurotoxicity during treatment with cytolytic viruses
WO2011056993A1 (en) 2009-11-04 2011-05-12 Yale University Compositions and methods for treating cancer with attenuated oncolytic viruses
CA2876209A1 (en) 2012-06-15 2013-12-19 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
SG11201506991VA (en) 2013-03-15 2015-10-29 Adaptive Biotechnologies Corp Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
US10874621B2 (en) 2013-10-17 2020-12-29 The Brigham And Women's Hospital, Inc. Cationic nanoparticles for co-delivery of nucleic acids and therapeutic agents
EP4331618A3 (de) 2014-05-09 2024-06-12 Yale University Hyperverzweigte polyglycerolbeschichtete partikel und verfahren zur herstellung und verwendung davon
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2017095751A1 (en) 2015-12-02 2017-06-08 Partikula Llc Compositions and methods for modulating cancer cell metabolism
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
JP2019533645A (ja) 2016-09-16 2019-11-21 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ
US20200085758A1 (en) 2016-12-16 2020-03-19 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
US12569497B2 (en) 2017-04-27 2026-03-10 The University Of Hong Kong Use of HCN inhibitors for treatment of cancer
US11478433B2 (en) 2017-06-23 2022-10-25 Yale University Nanomaterials with enhanced drug delivery efficiency
CN120718040A (zh) 2019-11-05 2025-09-30 佐治亚大学研究基金会股份有限公司 功能改性的美登木素生物碱及其组合物和使用方法
US20250163144A1 (en) 2021-07-27 2025-05-22 Novab, Inc. Engineered vlrb antibodies with immune effector functions
JP2025502630A (ja) 2021-12-08 2025-01-28 イエール・ユニバーシテイ ナノ粒子免疫原性組成物及びワクチン接種法
WO2023147552A1 (en) 2022-01-28 2023-08-03 University Of Georgia Research Foundation, Inc. Radiosensitizing compositions and methods of use thereof
JP2025529210A (ja) 2022-09-01 2025-09-04 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
EP4622631A1 (de) 2022-11-23 2025-10-01 University of Georgia Research Foundation, Inc. Zusammensetzungen und verfahren zur verwendung davon zur erhöhung der immunreaktionen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
DE69329656T2 (de) * 1992-12-22 2001-06-28 Ludwig Institute For Cancer Research, New York Methoden zur detektion und behandlung von individuen mit abnormalen hla-a2/tyrosinase-peptidantigenen exprimierenden zellen
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5856091A (en) * 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
US5554724A (en) * 1994-03-24 1996-09-10 University Of Leiden Isolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereof
US5851523A (en) * 1994-03-24 1998-12-22 Ludwig Institute For Cancer Research. Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules

Also Published As

Publication number Publication date
EP0845032B1 (de) 2001-11-28
JP3849102B2 (ja) 2006-11-22
US5821122A (en) 1998-10-13
CA2223694A1 (en) 1996-12-19
CA2223694C (en) 2003-06-24
AU5676996A (en) 1996-12-30
AU704934B2 (en) 1999-05-06
US5958711A (en) 1999-09-28
US5886145A (en) 1999-03-23
JP2001520506A (ja) 2001-10-30
DK0845032T3 (da) 2002-05-06
WO1996040039A3 (en) 2000-03-23
EP0845032A2 (de) 1998-06-03
ZA963907B (en) 1997-03-11
ES2167561T3 (es) 2002-05-16
DE69617440T2 (de) 2002-08-08
WO1996040039A2 (en) 1996-12-19
DE69617440D1 (de) 2002-01-10
EP0845032A4 (de) 2000-05-10
PT845032E (pt) 2002-05-31

Similar Documents

Publication Publication Date Title
ATE209680T1 (de) Isolierte nukleinsäuremoleküle, peptide die mit hla-a2 moleküle (mhc) komplexe bilden, sowie deren verwendungen
DE69433790T2 (de) Isolierte peptide, die mit mhc mulekül hla-c-klon 10 komplexe bilden und ihre verwendungen
ZA958039B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
FI954536A0 (fi) Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljintäantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö
NO960158D0 (no) Fremgangsmåte til diagnostisering av en lidelse ved å bestemme ekspresjon av GAGE-tumor-rejeksjonsantigenforlöpere
ATE258379T1 (de) Nukleinsäure, die für einen tumor abstossungsantigenvorläufer kodiert
DE69511399D1 (de) Isolierte, von mage-3 abgeleitete peptide, welche mit hla-a2 molekülen komplexieren
NZ302821A (en) isolated truncated nucleic acid molecules which code for GAGE tumour rejection antigen precursors
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
ES8704082A1 (es) Procedimiento para preparar un agente terapeutico a base de celulas tumorales humanas y eventualmente, neuraminidasa.
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
UY26170A1 (es) Antigeno (c42) asociados a tumores
TW372973B (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof
UA66753C2 (en) Immunostimulator and method for its production
CA2213001A1 (en) Isolated nucleic acid molecule encoding peptides which form complexes with mhc molecule hla-cw*1601 and uses thereof
DK0854727T3 (da) Tumorafstødelsesantigener, der præsenteres af HLA-B44-molekyler, og anvendelser af samme
CA2165435A1 (en) Isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0845032

Country of ref document: EP